Daiichi Sankyo Co., Ltd. Sponsored ADR (DSNKY)
OTC PINK OTC PINK Primary 
XFRA Summary
Daiichi Sankyo Company, Limited (DSNKY) Q1 2027 Earnings Call Transcript
Daiichi Sankyo Company, Limited (DSNKY) Q1 2027 Earnings Call Transcript
Daiichi Sankyo: Not Exciting Enough For This Market, Apparently
Daiichi Sankyo maintains strong growth prospects, driven by its expanding antibody-drug conjugate (ADC) pipeline and disciplined oncology development. Trastuzumab deruxtecan remains a key growth driver, with ongoing label expansions and pivotal trial readouts expected in 2H 2026 for first-line lung cancer. Datopotamab deruxtecan and raludotatug deruxtecan have secured new approvals and promising data, broadening the company's oncology franchise beyond HER2.
New Strong Sell Stocks for February 25th
DSNKY, LPX and RAL have been added to the Zacks Rank #5 (Strong Sell) List on February 25, 2026.
Daiichi Sankyo Co., Ltd. Sponsored ADR Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Michelle Dubey Yousif Capital Management LLC | 17,066 | $451,102.01 | $309,747.9 | -$141,354.11 | -31.34% |
 Peter Sigismondi Ramirez Asset Management, Inc. | 54 | $936.77 | $958.5 | $21.73 | 2.32% |
Daiichi Sankyo Co., Ltd. Sponsored ADR (DSNKY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Daiichi Sankyo Co., Ltd. Sponsored ADR ever had a stock split?
Daiichi Sankyo Co., Ltd. Sponsored ADR Profile
| Pharmaceuticals Industry | Healthcare Sector | Hiroyuki Okuzawa CEO | OTC PINK Exchange | 23381D102 CUSIP |
| JP Country | 20,171 Employees | 29 Sep 2026 Last Dividend | 9 Oct 2020 Last Split | - IPO Date |
Overview
Daiichi Sankyo Company, Limited is a global pharmaceutical company founded in 1899, with its headquarters in Tokyo, Japan. It operates across various regions including Japan, North America, Europe, and other international markets. The company is dedicated to the manufacture and sale of pharmaceutical products. Their portfolio includes a variety of drugs for treating cancer, iron deficiency, hypertension, cholesterol, diabetes mellitus, migraine attacks, osteoporosis, neuropathic pain, and seizures, among others. Additionally, they provide vaccines for several infectious diseases. Daiichi Sankyo has established strategic collaborations with notable entities like Merck & Co., Inc. and AstraZeneca UK Limited for the development of anti-cancer drugs.
Products and Services
Enhertu: A treatment for patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors.
Turalio: An oral small molecule targeting CSF1R, KIT, and FLT3-ITD mutation for specific cancers.
Vanflyta: A FLT3 inhibitor used in the treatment of adult patients with acute myeloid leukemia.
Injectafer: A ferric carboxymaltose injection to address iron deficiency.
Liziana and Savaysa: Anticoagulants acting as direct factor Xa inhibitors.
Antihypertensive Agents (Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, Sevikar HCT): A series of drugs designed to treat hypertension.
Nilemdo: An oral treatment that lowers cholesterol.
Nustendi: A combination tablet of bempedoic acid and ezetimibe for cholesterol reduction.
Efient: An anti-platelet agent.
Diabetes Treatments (Canalia and Tenelia): Medications for the management of type 2 diabetes mellitus.
Migraine Treatments (Emgalty and Reyvow): Drugs to treat migraine attacks.
Pralia: A treatment for osteoporosis and inhibitor of the progression of bone erosion associated with rheumatoid arthritis.
Ranmark: Addresses bone complications from bone metastasis from tumors.
Tarlige: For the treatment of neuropathic pain.
Venofer: Treats iron deficiency anemia.
Vimpat: An anti-seizure medication.
Vaccines: Providing protection against COVID-19, influenza, H5N1 influenza, measles/rubella, and mumps.
